Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Transcenta reports antitumor responses with TST-001 in gastric cancer

July 5, 2021

Sanofi initiates early clinical studies of SAR-444245

July 5, 2021

Neoantigen-specific cytotoxic T cells show in vivo efficacy in Ewing sarcoma

July 2, 2021

I-Mab provides updates for its 4-1BB bispecific antibody portfolio

July 2, 2021

Phase Ib data for NIS-793 plus spartalizumab in patients with advanced solid tumors

July 1, 2021

Updated phase I/II data for galinpepimut-S plus Keytruda in WT1-positive ovarian cancer

July 1, 2021

Dosing begins in phase Ib/II study of TTI-621 with doxorubicin in leiomyosarcoma

June 30, 2021

Elicio initiates phase I/II AMPLIFY-201 study of ELI-002 in KRAS-driven cancers

June 30, 2021

FDA clears IND application for CLN-619 for the treatment of solid tumors

June 30, 2021

Ori-CAR-001 CAR T-cell therapy targeting glypican-3 safe in phase I study

June 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...
In monkeys, enhanced TB vaccine dissolves after inducing protection
BioWorld Science
An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin...
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...